LoginCompartmentalisation of death receptor signalling in cancer
31 August 2026 at 08:00
Oncogenesis, Published online: 31 August 2026; doi:10.1038/s41389-026-00654-w
Compartmentalisation of death receptor signalling in cancerNormal view
Received — 10 September 2026
⏭
Oncogenesis - nature.com science feeds
-
Oncogenesis - nature.com science feeds
-
Compartmentalisation of death receptor signalling in cancer
Oncogenesis, Published online: 31 August 2026; doi:10.1038/s41389-026-00654-wCompartmentalisation of death receptor signalling in cancer
-
-
-
NKCC1 as a regulator of stemness and redox balance in colorectal cancer
Oncogenesis, Published online: 31 August 2026; doi:10.1038/s41389-026-00651-zNKCC1 as a regulator of stemness and redox balance in colorectal cancer
-
NKCC1 as a regulator of stemness and redox balance in colorectal cancer
31 August 2026 at 08:00
Oncogenesis, Published online: 31 August 2026; doi:10.1038/s41389-026-00651-z
NKCC1 as a regulator of stemness and redox balance in colorectal cancer-
-
Stanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis
Oncogenesis, Published online: 29 August 2026; doi:10.1038/s41389-026-00653-xStanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis
-
Stanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis
29 August 2026 at 08:00
Oncogenesis, Published online: 29 August 2026; doi:10.1038/s41389-026-00653-x
Stanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis-
-
CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4Rα/STAT3 pathway and stabilizing membranous SLC7A11
Oncogenesis, Published online: 21 August 2026; doi:10.1038/s41389-026-00650-0CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4Rα/STAT3 pathway and stabilizing membranous SLC7A11
-
CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4Rα/STAT3 pathway and stabilizing membranous SLC7A11
21 August 2026 at 08:00
Oncogenesis, Published online: 21 August 2026; doi:10.1038/s41389-026-00650-0
CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4Rα/STAT3 pathway and stabilizing membranous SLC7A11-
-
A novel combinatorial treatment for Neurofibromatosis type 1 tumours revealed through cross-species genetic analysis
Oncogenesis, Published online: 21 August 2026; doi:10.1038/s41389-026-00643-zA novel combinatorial treatment for Neurofibromatosis type 1 tumours revealed through cross-species genetic analysis
-
A novel combinatorial treatment for Neurofibromatosis type 1 tumours revealed through cross-species genetic analysis
21 August 2026 at 08:00
Oncogenesis, Published online: 21 August 2026; doi:10.1038/s41389-026-00643-z
A novel combinatorial treatment for Neurofibromatosis type 1 tumours revealed through cross-species genetic analysis-
-
Dual downregulation of HRK and BAD promotes BCL-xL-mediated docetaxel resistance in prostate cancer
Oncogenesis, Published online: 20 August 2026; doi:10.1038/s41389-026-00652-yDual downregulation of HRK and BAD promotes BCL-xL-mediated docetaxel resistance in prostate cancer
-
Dual downregulation of HRK and BAD promotes BCL-xL-mediated docetaxel resistance in prostate cancer
20 August 2026 at 08:00
Oncogenesis, Published online: 20 August 2026; doi:10.1038/s41389-026-00652-y
Dual downregulation of HRK and BAD promotes BCL-xL-mediated docetaxel resistance in prostate cancer-
-
The role of m<sup>6</sup>A reader YTHDF2 in lymphangiogenesis via RNF43/WNT5B in oral squamous cell carcinoma
Oncogenesis, Published online: 20 August 2026; doi:10.1038/s41389-026-00648-8The role of m6A reader YTHDF2 in lymphangiogenesis via RNF43/WNT5B in oral squamous cell carcinoma
-
The role of m<sup>6</sup>A reader YTHDF2 in lymphangiogenesis via RNF43/WNT5B in oral squamous cell carcinoma
20 August 2026 at 08:00
Oncogenesis, Published online: 20 August 2026; doi:10.1038/s41389-026-00648-8
The role of m6A reader YTHDF2 in lymphangiogenesis via RNF43/WNT5B in oral squamous cell carcinoma-
-
Disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer to ferroptosis and enzalutamide therapy
Oncogenesis, Published online: 11 August 2026; doi:10.1038/s41389-026-00649-7Disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer to ferroptosis and enzalutamide therapy
-
Disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer to ferroptosis and enzalutamide therapy
11 August 2026 at 08:00
Oncogenesis, Published online: 11 August 2026; doi:10.1038/s41389-026-00649-7
Disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer to ferroptosis and enzalutamide therapy
Received — 27 May 2026
⏭
Oncogenesis - nature.com science feeds
-
-
Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways
Oncogenesis, Published online: 21 May 2026; doi:10.1038/s41389-026-00628-yCatestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways
-
Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways
21 May 2026 at 08:00
Oncogenesis, Published online: 21 May 2026; doi:10.1038/s41389-026-00628-y
Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways-
-
Metabolic vulnerabilities in pleural mesothelioma
Oncogenesis, Published online: 20 May 2026; doi:10.1038/s41389-026-00625-1Metabolic vulnerabilities in pleural mesothelioma
-
Metabolic vulnerabilities in pleural mesothelioma
20 May 2026 at 08:00
Oncogenesis, Published online: 20 May 2026; doi:10.1038/s41389-026-00625-1
Metabolic vulnerabilities in pleural mesothelioma-
-
Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML
Oncogenesis, Published online: 16 May 2026; doi:10.1038/s41389-026-00623-3Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML
-
Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML
16 May 2026 at 08:00
Oncogenesis, Published online: 16 May 2026; doi:10.1038/s41389-026-00623-3
Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML-
-
SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8<sup>+</sup> memory T cell responses
Oncogenesis, Published online: 15 May 2026; doi:10.1038/s41389-026-00627-zSHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8+ memory T cell responses
-
SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8<sup>+</sup> memory T cell responses
15 May 2026 at 08:00
Oncogenesis, Published online: 15 May 2026; doi:10.1038/s41389-026-00627-z
SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8+ memory T cell responses-
-
Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma
Oncogenesis, Published online: 15 May 2026; doi:10.1038/s41389-026-00629-xMetabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma
-
Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma
15 May 2026 at 08:00
Oncogenesis, Published online: 15 May 2026; doi:10.1038/s41389-026-00629-x
Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma-
-
Imbalances of mitochondrial dynamics in solid tumors
Oncogenesis, Published online: 12 May 2026; doi:10.1038/s41389-026-00620-6Imbalances of mitochondrial dynamics in solid tumors
-
Imbalances of mitochondrial dynamics in solid tumors
12 May 2026 at 08:00
Oncogenesis, Published online: 12 May 2026; doi:10.1038/s41389-026-00620-6
Imbalances of mitochondrial dynamics in solid tumors-
-
Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU
Oncogenesis, Published online: 08 May 2026; doi:10.1038/s41389-026-00621-5Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU
-
Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU
8 May 2026 at 08:00
Oncogenesis, Published online: 08 May 2026; doi:10.1038/s41389-026-00621-5
Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU-
-
Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy
Oncogenesis, Published online: 07 May 2026; doi:10.1038/s41389-026-00622-4Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy
-
Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy
7 May 2026 at 08:00
Oncogenesis, Published online: 07 May 2026; doi:10.1038/s41389-026-00622-4
Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy-
-
PRMT6-mediated EZH2 arginine methylation is critical for breast cancer development
Oncogenesis, Published online: 19 April 2026; doi:10.1038/s41389-026-00619-zPRMT6-mediated EZH2 arginine methylation is critical for breast cancer development
-
PRMT6-mediated EZH2 arginine methylation is critical for breast cancer development
19 April 2026 at 08:00
Oncogenesis, Published online: 19 April 2026; doi:10.1038/s41389-026-00619-z
PRMT6-mediated EZH2 arginine methylation is critical for breast cancer development-
-
Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer
Oncogenesis, Published online: 17 April 2026; doi:10.1038/s41389-026-00615-3Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer
-
Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer
17 April 2026 at 08:00
Oncogenesis, Published online: 17 April 2026; doi:10.1038/s41389-026-00615-3
Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer-
-
SREBP2 regulates CCDC25 expression and promotes tumor metastasis in Triple-Negative Breast Cancer
Oncogenesis, Published online: 13 April 2026; doi:10.1038/s41389-026-00614-4SREBP2 regulates CCDC25 expression and promotes tumor metastasis in Triple-Negative Breast Cancer
-
SREBP2 regulates CCDC25 expression and promotes tumor metastasis in Triple-Negative Breast Cancer
13 April 2026 at 08:00
Oncogenesis, Published online: 13 April 2026; doi:10.1038/s41389-026-00614-4
SREBP2 regulates CCDC25 expression and promotes tumor metastasis in Triple-Negative Breast Cancer
Received — 13 April 2026
⏭
Oncogenesis - nature.com science feeds
-
-
Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Oncogenesis, Published online: 10 April 2026; doi:10.1038/s41389-026-00616-2Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
-
Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
10 April 2026 at 08:00
Oncogenesis, Published online: 10 April 2026; doi:10.1038/s41389-026-00616-2
Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma